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Summary Amongst 14,000 women with breast cancer treated between 1946 and 1982, 194 developed a
second primary tumour in the contralateral breast more than one year after diagnosis of the first primary.
The radiation dose to the contralateral breast was calculated for each member of this group and also for
members of a control group matched for age, year of diagnosis and survival time. Comparison of the groups
provides no evidence for radiation induced carcinogenesis on the contralateral breast in these patients.
When patients with breast cancer receive post-
operative radiotherapy, tissues adjacent to the
irradiated volume, and in particular the contra-
lateral breast, receive a significant radiation dose.
Women with a first breast cancer have been shown
to be at an elevated risk of developing a second
breast primary (see, for example, Hislop et al.,
1984) and may be more sensitive to the effects of
carcinogens such as radiation. Previous studies of
radiation induced breast cancer have been largely
composed of women of younger age than those
who receive treatment for breast cancer. This study
attempts to determine whether second primary
breast neoplasms in patients receiving radiotherapy
can be related to the radiation dose.
Materials and methods
Study groups
The A. Maxwell Evans Clinic (AMEC) is a regional
referral centre for cancer treatment in the province
of British Columbia, Canada. Approximately
14,000 women with breast cancer were seen between
1946 and 1982. All pathology is routinely reviewed
by members of a small group of staff pathologists.
Prior to 1976 an index of all suspected cases of
bilateral disease seen at this clinic was routinely
maintained. Since 1968 all cases of cancer have
been routinely reported to a province-wide cancer
registry. Using these two sources patients were
selected who were seen at AMEC within 12 months
of the diagnosis of their first primary infiltrating
cancer of the breast and who also satisfied the
following criteria:
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(a) the tumour in the second breast was infiltrating,
and
(b) the tumour was not associated with widespread
metastatic disease, and
(c) either the histological type of the second
primary was distinct from the first carcinoma,
or the second primary was associated with in-
situ change.
Attention was restricted to cases whose first
primary was diagnosed between 1946 and 1982 and
whose second primary was diagnosed prior to 1984
and more than 12 months after their first diagnosis.
Information was extracted from the medical
record, including demographic variables, infor-
mation on the treatment plan and data on the
tumour characteristics. All patients seen at AMEC
are routinely followed for life either actively or by
letter depending on disease status. Where
information was missing subjects were excluded,
leaving a total of 194 cases available for this study.
A control group was assembled from the patients
with infiltrating breast cancer seen at AMEC who
did not develop a second primary in which each
patient was individually matched to a case using
the following criteria:
(a) age at diagnosis of the first primary±two years.
(b) year of diagnosis of the first primary±one year.
(c) follow-up time at least as great as the elapsed
time between the diagnosis of the first and
second breast cancers in the corresponding case.
Technique and dosimetry
Most of the patients were post-mastectomy.
Throughout the study period, whether using ortho-
voltage X-rays or 60Co y-rays, the standard
radiation treatment has remained unchanged and
has consisted of either a 3-field or a 5-field plan.
The 5-field plan consists of a parallel opposed pair
tangential to the chest wall and also internal
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Table I Standard 5-field radiation treatment prescription
(1946-1982)
Given dose Target dose
(cGy) (cGy)
Internal mammary 4,000
Anterior
supraclavicular
and axilla 4,000
Posterior axilla As required to 3,750
deliver T.D.
Chest wall tangents As required to 4,000
deliver T.D.
All fields except posterior axillary field treated in 16
fractions in 22 days.
Field to posterior axilla treated in 8 fractions over 22
days.
mammary, supraclavicular and posterior axilla
fields to treat the internal mammary, supracla-
vicular and axillary lymph nodes. (See Table I). The
given dose required to produce the specified target
dose depends upon the size of the individual
patient. In the three field treatment, the tangential
pair to the chest wall is omitted. The choice
between these two plans is determined primarily by
the surgical technique and is not dependent on the
stage of the disease.
For those patients treated by 60Co, the radiation
dose to the contralateral breast in the study group
was estimated by measuring the dose in newly
referred breast cancer patients receiving radio-
therapy in 1980. The patients for measurement were
selected at random, but to verify that they were
representative of the group as a whole, the
separation of the tangential pair in patients treated
with 5 fields was used as a convenient measure of
chest size. For 12 patients upon whom dose
measurements were made the mean separation was
18.9+ 1.2cm (s.d.) compared with a mean
separation of 19.1 + 1.8cm in 100 consecutive
patients. A tape containing five pairs of lithium
fluoride thermoluminescent dosimeters was placed
on the contralateral breast, running from the medial
to the lateral border at the level of the nipple. The
central pair of dosimeters was always placed at the
nipple, the innermost pair was placed 0.5cm from
the edge of the internal mammary field and the
outermost pair at the mid-axillary line (to represent
the lateral border of the breast). The remaining
pairs were placed midway between the central and
edge dosimeters. On some of the patients, similar
measurements were made with dosimeters running
in the cephalic-caudal direction. However, there was
very little variation in this direction (< 10%) in the
total dose from all fields, so measurements were
usually confined to the medial-lateral direction.
For those patients treated in the early years by
orthovoltage X-rays, the radiation dose to the contra-
lateral breast was estimated from measurements
made upon a phantom using 250kv X-rays (H.V.L.
2.5 mm Cu). For these measurements, a small
ionisation chamber with walls of tissue-equivalent
plastic (Shonka A 150) was placed successively in the
same positions as the thermoluminescent dosimeters,
and the dose delivered by each of the treatment
fields determined as a percentage of the given dose.
Regardless of whether the treatment was given by
X-rays or 60Co y-rays, and regardless of whether
three or five fields were used, the dose to the
contralateral breast from all treatment fields always
increased systematically from the outer to the inner
side of the breast. (see Table II and Figure 1). The
dose to the lateral border was about 60% (±5%) of
that at the nipple in all cases. The dose at the
medial border was rather more than twice the
nipple dose for the 60Co irradiations and three or
four times the nipple dose for the X-radiations.
However, the dose decreases more rapidly for X-
rays than for 60Co y-rays as the distance from the
border increases. In addition there is more breast
tissue lateral than medial to the nipple. For these
reasons the mean dose to the total breast tissue in
Table H Dose to the contralateral breast
Dose distribution across contralateral breast
Mean
Medial border Nipple Lateral border dose
(cGy) (cGy) (cGy) (cGy)
Co60a All 5 fields 710 (190) 320(59) 178 (26) 327
Nodal fields only 470 (114) 191 (30) 125 (15) 218
250kvb All 5 fields 784 204 113 203
Nodal fields only 619 136 83 138
aThe figures in brackets are the s.d. of the measured doses. The major component of
this variance is due to differences in patient size. bMeasurements on a single medium
sized phantom (Tangential pair separation of 19cm).RADIATION DOSE AND SECOND BREAST CANCER 321
A A'
B'
Figure 1 Dose to contralateral breast for 5 field
treatment with 60Co y radiation. AA'-represents the
level of the lower edge of tangential fields. BB'-
represents the edge (i.e. 50% isodose) of the internal
mammary field.
considerable dose-gradient from lateral to medial
border.
In the early years, the medial member of the
tangential pair was frequently positioned in such a
way that the internal mammary chain was treated
by this field instead of by a separate internal
mammary field. In such cases the dose delivered to
the contralteral nipple has been calculated as if an
internal mammary field had been used with the
same given dose as the medial member of the
tangent pair.
Results
Of 194 case-control pairs, 169 cases and 163
controls were treated by radiation. The distribution
of doses within the X-ray and 60Co radiation
groups is shown separately in Figure 2. The mean
dose at the contra-lateral nipple received by all
members of the case group is compared with that
for the controls in Table III. For the group as a
whole there is no significant difference. If the
comparison is restricted to pairs in which the
second primary was diagnosed either more than 5
all cases is approximately equal to the nipple dose.
(Our estimate of the mean dose assumes there is on
average twice as much breast tissue lateral as
medial of the nipple. This value was derived from
examination of CT scans in newly referrred patients
in the same age group as the study group). The
decrease of dose with increasing distance from the
midline is to be expected since the dose to the
contralateral breast is due to radiation scattered
from the tissues on the directly irradiated side. For
the same reason, differences between the dose at the
surface and underlying breast tissue are small in
comparison with the lateral variation. (This is of
course quite different from the situation which
exists in chest radiography or mammography.)
Measurements upon a medium sized phantom
(tangential pair separation 19cm.) gave depth doses
at 3.5cm deep to the nipple of 107% and 109%
respectively for 5 and 3 field cobalt irradiation and
124% and 139% respectively for 5 and 3 field
orthovoltage irradiation.
In order to determine the doses received by the
patients in the study group, the ratio of the mean
dose at the nipple in the contra-lateral breast to the
dose delivered by each of the treatment fields, as
determined experimentally, was assumed to be
constant and applicable to the patients in the study.
From the treatment records of the study group, the
dose to the contralateral nipple could then be
calculated. This will henceforth be called the "breast
dose", but it is important to remember the very
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Figure 2 Distribution of mean contralateral nipple
doses amongst cases and controls. (a) Prior to 1962; all
but two irradiated patients were treated with
orthovoltage X-rays. (b) from 1962 onwards; all but
two irradiated patients were treated with 60Co y rays.
(EJ) all time intervals; (1a) time to second primary
>5gy; (-) time to second primary >10y; l denotes
mean dose.322 V.E. BASCO et al.
Table III Mean dose to contralateral nipple by year ofdiagnosis of cases and time to the second primary
Nipple dose in cGyb % Change in
Year of Time to relative P
Diagnosisa Second primary # Subjects Case group Control group risk per cGy Valuec
ALL ALL 194 154 (7) 157 (8) -0.04 0.82
ALL >5 yrs 106 141 (8) 154 (10) -0.23 0.17
ALL > 10 yrs 44 127 (12) 138 (12) -0.20 0.34
< 1962 ALL 76 104 (5) 118 (7) -0.79 0.09
<1962 5 yrs 57 103 (6) 123 (8) -1.22 0.02
< 1962 > 10 yrs 33 100 (9) 122 (13) -0.90 0.09
,1962 ALL 118 186 (10) 181 (12) 0.06 0.65
> 1962 5 yrs 49 186 (14) 189 (17) -0.04 0.88
> 1962 > 10 years 11 206 (29) 184 (28) 0.18 0.59
aPrior to 1962 all but 2 irradiated subjects were irradiated by X-ray. From 1962 onwards all except 2
irradiated subjects were irradiated by 60Co. bFigures in brackets are s.e. cWilcoxon signed rank test.
Table IV Mean dose to contralateral nipple by age and year ofdiagnosis of case
Nipple dose in cGya % Change in
Year of Age at relative P
diagnosis diagnosis # Subjects Case group Control group risk per cGy valueb
ALL >40 30 113 (11) 130 (17) -0.61 0.62
ALL >40, <50 67 159 (11) 164 (13) -0.07 0.92
ALL >50, <60 56 166 (13) 168 (14) -0.03 0.66
ALL 60+ 41 161 (19) 150 (22) 0.16 0.50
< 1962 40 23 113 (7) 129 (16) -1.26 0.58
<1962 >40, 50 27 99 (10) 113 (11) -1.30 0.09
<1962 >50, 60 15 98 (17) 127 (10) -1.50 0.20
< 1962 60+ 11 109 (11) 99 (21) 0.31 0.80
1962 40 7 114 (45) 136 (55) -0.31 0.69
>1962 >40, <50 40 199 (13) 198 (20) 0.01 0.99
>1962 >50, <60 41 191 (16) 182 (18) 0.11 0.91
,1962 60+ 30 181 (24) 168 (28) 0.15 0.51
aFigures in brackets are s.e. bWilcoxon signed rank test.
years, or more than 10 years after irradiation, there
is no significant difference. Similarly there was no
significant increase in the relative risk in any
subgroups. There was no significant difference
between the cases and controls when the X-ray and
60Co irradiated groups were analyzed separately,
with the exception of a lower dose among the cases
receiving X-radiation whose second primary
developed more than 5 years later.
The data analysed by age at irradiation are given
in Table IV. No statistically significant differences
between cases and controls were seen at any age.
Matched logistic regression was used to examine
the relationship between radiation dose and the
development of a second primary controlling for
other factors. After controlling for clinical stage,
pathologic nodal involvement (0, 1-3, 4+) and
family history of breast cancer in a first degree
relative (no/yes), a term RD was included where D
was the calculated nipple dose and R was the
relative risk per 1OOcGy. Using all cases we found
R =0.99 (P =0.95), with an 95% confidence
interval for R of (0.76, 1.30). For those diagnosed 5
years or more after their first tumour, we found
R=0.94 (P=0.69), with an -95% confidence inter-
val of (0.69, 1.26). For those diagnosed 10 years or
more after their first tumour, we found R=0.83
(P=0.57), with confidence interval (0.45, 1.54). Thus
in no instance was R significantly different from
unity and hence there was no evidence that second
breast cancer risk was related to radiation dose.
Since the radiation dose always increases from
the lateral to the medial border of the contralateral
breast (Table II), some further information can be
derived from the location of the second primary
tumour within the breast. When all tumours areRADIATION DOSE AND SECOND BREAST CANCER
Table V Distribution of tumours by locationa
No. in No. in % in P
Patient Population Tumour outerhalf innerhalf innerhalf value
Time to Nipple dose
second primary in cGy
ALL ALL First 88 32 27 1.00
Second 89 31 26
ALL >0 ~~First 81 29 26 10 ALL >0 °Second 82 28 25 100
>,5 yr>0 ~ First 46 20 30 10 >5yr >0 Second 45 21 32 1.0
>5 yr >0, <200 Second 36 16 31 1.00
>5 yr >200 seFirst 10 4 29 1.00 ~~5yr ~~200 ~Second 9 5 36 10
aStudy subjects considered are only those for which both
either the inner or outer half. bMcNemar x2.
considered there is no difference between the first
and second tumours in the location within the
breast (Table V). If one considers only those
tumours appearing after 5 years or only those
occurring after five years who received more than
200cGy nipple dose, there is still no significant
increase in the percentage of tumours occurring in
the inner half.
Discussion
It is important to recognize that this study group is
not typical of the general female population. Firstly,
patients in both the case group and the control
group have already developed a breast cancer and
can therefore be expected to include women with a
concentration of risk factors for breast cancer which
increase the risk of developing a cancer in the other
breast. Secondly, the average age at irradiation was
51.3 years (range 23 to 78 years), thus the patients
were substantially older than most other groups in
whom the carcinogenic effect of radiation to the
breast has been studied e.g. tuberculosis patients
(Boice & Monson, 1977), mean age 26 years, post
partum mastitis patients (Shore et al., 1977), mean
age 27 years, atomic bomb survivors (McGregor et
al., 1977), mean age 33 years, benign breast disease
patients (Baral et al., 1977) 38 years. A recent
Canadian fluoroscopy series (Howe, 1985) also
involves women irradiated predominantly at a
younger age. Age specific analyses of estimated risks
are summarized by Howe (Personel com-
munication) and in the BEIR report (1980) and
by Land et al. (1980). All suggest a decreased risk
with increasing age at exposure. However, the data
tumours could be definitely assigned to
on patients exposed to radiation over the age of 40
are based on very few cases. The patients with
benign breast disease showed a decreasing risk with
increasing age up to age 60, but in the 60-64 age
group the risk was reported to be increased.
However, the estimate is based on only two breast
cancer cases observed. Boice et al. (1979) concluded
that the risk of radiogenic breast cancer is greatest
for adolescent exposure and is present for all ages
at exposure, but the data are insufficient to prove
or disprove that the risk decreases with increasing
age.
The question of latent period is of interest. The
medical series all show a latent period of at least 5
years, more usually 10-20 -years, before an increase
in the risk of breast cancer is demonstrated. But in
the atomic bomb survivors the latent period is
dependent on the age at irradiation, and appears to
correspond to the time taken after exposure to
reach the age at which breast cancer incidence
bcomes significant in Japan. The recent Canadian
fluoroscopy series also suggests the possibility that
radiogenic breast cancer manifests itself when the
woman reaches an age for a significant risk of
breast cancer to have occurred.
If radiation dose is important in the genesis of
the second primary tumour an increased incidence
would be expected to correlate with an increased
dose, since in all major series studied previously, the
incidence can be well represented as increasing
linearly with dose to the highest doses recorded
(BIER, 1980; Schmitz-Feuerhake & Carbonell,
1983). (In one series only, the Rochester mastitis
series, which is exceptional in that single doses were
of the order of 1OOcGy, the data above 400cGy,
can be fitted rather better if a cell-killing term is
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introduced, but the data are still compatible with a
linear relation). If we assume for the sake of
argument that the BEIR estimate of 6.6 radiation
induced cancers per 104 woman-years-Gray is
applicable to this group of patients, a mean breast
dose of 154cGy would result in an increased
incidence of 10 cases per 104 woman-years (wy).
The observed incidence of second breast cancers in
B.C. is 38 per 104wy compared compared with an
incidence for first breast cancers of 19 per 104
cancers (Hislop et al., 1984), i.e. the excess risk of a
second primary compared to a first, is 19 per
104wy. Thus using the BEIR estimate would
suggest that approximately half of the excess risk
might be attributed to radiation.
Nevertheless, in our study, there is no evidence
that the patients developing a second primary
received a higher radiation dose than the control
group despite substantial individual variation in
doses. There is no evidence of a correlation between
risk and mean dose in the irradiated group and no
evidence of an increase in tumours in the more
heavily irradiated inner half of the breast compared
with the outer half. This last comparison directly
controls for a variety of host factors. Thus there
was no evidence that radiation was a significant
cause of the second primaries.
Two reported series, Schell et al. (1982) and
McCredie et al. (1975), have failed to show an
increased risk of developing a second primary
breast cancer in patients receiving post-operative
irradiation therapy. The study by McCredie et al is
of particular relevance to the present study in that
the patients were all referred to a regional Canadian
Cancer Clinic and in all likelihood had a similar
demographic background.
A recent and much larger series analyzed from
the Connecticut Tumor Registry (Hankey et al.,
1983) also showed no consistent effect of irradiation
apart from a borderline increase in long term risk
(greater than 10 years) present only in patients
treated between 1960 and 1975 and not evident in
the analysis of patients treated in the period 1935-
59. The radiation dose to the contralateral breast
was not determined in the Connecticut Registry
series.
Conclusion
This study provides no evidence for an increased
risk of radiation induced cancer in the contralateral
breast during the remaining lifespan of these
patients. This finding is of particular importance for
women with primary tumours suitable for treatment
by partial mastectomy, axillary node dissection and
radiation therapy, who have been concerned about
the risk to the contralateral breast from irradiation
and who are considering this therapeutic option vis
a vis modified radical mastectomy alone. This
group of women are already at high risk for
development of a second breast cancer but this
study provides no evidence that they are especially
susceptible to radiation induced cancers.
Most of the patients included in this study were under the
care of Dr G.M. Crawford whose co-operation is
gratefully acknowledged. We would also like to thank
Anne Burgess, Margaret Fung and Eileen Swait for
technical assistance.
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